Description
A Triple-Receptor Agonist Peptide (GLP-1/GIP/Glucagon) for Metabolic Research
Retatrutide is a synthetic 39-amino-acid peptide engineered to engage the GLP-1, GIP, and glucagon receptors. As of 2026 it remains an investigational compound with no FDA approval for any indication. Amino Architects supplies Retatrutide strictly as a lyophilized reference compound for laboratory research; this listing is not affiliated with, and is not a substitute for, any approved or investigational drug product.
Molecular Profile
- Compound: Retatrutide (triple agonist: GLP-1 / GIP / glucagon receptor)
- Dosage: 15mg lyophilized peptide per vial
- Purity: ≥99.7%, TFA-free
- Form: Sterile lyophilized powder for reconstitution
Research Background
Retatrutide’s tri-receptor pharmacology has been characterized in published, sponsor-run clinical trials studying receptor activation across GLP-1, GIP, and glucagon pathways. It is referenced in metabolic-research literature as a triple-agonist tool compound; published results reflect the sponsor’s own investigational drug product, not this research-grade reference material.
Storage & Handling
- Store lyophilized powder at or below -4°F prior to reconstitution
- Refrigerate at 36–46°F after reconstitution with bacteriostatic water
- For laboratory research use only. Not for human consumption.
